Publications by authors named "Roberto Collado-Borrell"

Claim this Profile
I
ICANS risk model in CD19 CAR-T therapy: insights from serum and CSF cytokine profiling.
Marina Gomez-Llobell, Carlos Serra Smith, Daniel Gómez-Costas, Ignacio Gómez-Centurión, Jose Manuel García Domínguez, Roberto Collado-Borrell

Bone Marrow Transplant· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a Questionnaire to Assess the Usability of and User Experience with Mobile Health Applications.
Anna de Dios López, Jordi Real, Claudia Meza, Alicia Borras-Santos, Roberto Collado-Borrell

Healthcare (Basel)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe neutropenia probably caused by enzalutamide and abiraterone in a prostate cancer patient.
Beatriz Somoza-Fernández, Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Sara Pérez-Ramírez, Cristina Villanueva-Bueno

J Oncol Pharm Pract· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy.
Elena Ramos-Ruperez, Vicente Escudero-Vilaplana, Paula Ruiz-Briones, Roberto Collado-Borrell, Cristina Villanueva-Bueno

Front Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complementary and alternative medicine in cancer patients: characteristics of use and interactions with antineoplastic agents.
Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Patricia Gómez Martínez-Sagrera, Cristina Villanueva-Bueno, José Luis Revuelta-Herrero

J Cancer Res Clin Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Possible heart failure caused by osimertinib in a lung cancer patient.
Paula Ruiz-Briones, Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Juan Vicente-Valor, Rosa Alvarez

J Oncol Pharm Pract· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1.
Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Javier De Castro, Amelia Insa, Alex Martínez

J Med Econ· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain.
Javier De Castro, Amelia Insa, Roberto Collado-Borrell, Vicente Escudero-Vilaplana, Alex Martínez

BMC Pulm Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A smartphone app to improve the safety of patients undergoing treatment with oral antineoplastic agents: 4 years of experience in a university hospital.
Cristina Villanueva-Bueno, Roberto Collado-Borrell, Vicente Escudero-Vilaplana, José Luis Revuelta-Herrero, María Belén Marzal-Alfaro

Front Public Health· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation and evaluation of a home pharmaceutical care model through Telepharmacy.
Cristina Villanueva-Bueno, Roberto Collado-Borrell, Carmen Guadalupe Rodríguez-González, Vicente Escudero-Vilaplana, Esther Chamorro-de-Vega

Farm Hosp· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential negative pharmacodynamic interaction of spironolactone and abiraterone in two prostate cancer patients.
Juan Vicente-Valor, Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Cristina López-López, Cristina Villanueva-Bueno

J Oncol Pharm Pract· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smartphone-Based Ecological Momentary Assessment for the Measurement of the Performance Status and Health-Related Quality of Life in Cancer Patients Under Systemic Anticancer Therapies: Development and Acceptability of a Mobile App.
Vicente Escudero-Vilaplana, Lorena Romero-Medrano, Cristina Villanueva-Bueno, Marta Rodríguez de Diago, Alberto Yánez-Montesdeoca, Roberto Collado-Borrell

Front Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application.
Sebastián García-Sánchez, Roberto Collado-Borrell, Eva González-Haba, José Luis Revuelta-Herrero, Vicente Escudero-Vilaplana

Front Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining a Standard Set of Patient-Reported Outcomes for Patients With Advanced Ovarian Cancer.
Vicente Escudero-Vilaplana, Elsa Bernal, Gema Casado, Roberto Collado-Borrell, Raúl Diez-Fernández

Front Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of a methodology to assess patient reported outcomes in lung cancer patients: The PeOpLe (Patient-reported Outcomes in Lung cancer ) study protocol.
Cristina Villanueva-Bueno, Roberto Collado-Borrell, José Luis Revuelta-Herrero, Ana Beatriz Fernández-Román, Gema Casado-Abad

Farm Hosp· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thalidomide as treatment of refractory thoracic Rosai-Dorfman disease.
Angela Hoyo-Muñoz, Roberto Collado-Borrell, Vicente Escudero-Vilaplana, Mariana Bastos-Oreiro, Ana Herranz-Alonso

J Clin Pharm Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes and mobile applications. A review of their impact on patients' health outcomes.
Roberto Collado-Borrell, Vicente Escudero-Vilaplana, Álvaro Narrillos-Moraza, Cristina Villanueva-Bueno, Ana Herranz-Alonso

Farm Hosp· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mobile Apps for Hematological Conditions: Review and Content Analysis Using the Mobile App Rating Scale.
Álvaro Narrillos-Moraza, Patricia Gómez-Martínez-Sagrera, Miguel Ángel Amor-García, Vicente Escudero-Vilaplana, Roberto Collado-Borrell

JMIR Mhealth Uhealth· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medication guide for the perioperative management of oral antineoplastic agents in cancer patients.
Cristina Villanueva-Bueno, Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Álvaro Giménez-Manzorro, Almudena Ribed

Expert Opin Drug Saf· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice.
Juan Vicente-Valor, Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Sara Pérez-Ramírez, Cristina Villanueva-Bueno

Expert Opin Drug Metab Toxicol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice.
Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Maria Del Monte-Millán, Angela Hoyo-Muñoz, Patricia Gómez Martínez-Sagrera

Support Care Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aggressiveness of end-of-life cancer care: what happens in clinical practice?
Estela García-Martín, Vicente Escudero-Vilaplana, Bárbara Fox, Roberto Collado-Borrell, Belén Marzal-Alfaro

Support Care Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective.
María Belen Marzal-Alfaro, Vicente Escudero-Vilaplana, Jose Luis Revuelta-Herrero, Roberto Collado-Borrell, Ana Herranz-Alonso

Front Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain.
Esther Chamorro-de-Vega, Carmen-Guadalupe Rodriguez-Gonzalez, Silvia Manrique-Rodríguez, Elena Lobato-Matilla, Felix García-Moreno, Roberto Collado-Borrell

Expert Rev Clin Pharmacol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost of Venous Thromboembolic Disease in Patients with Lung Cancer: Costecat Study.
Ana Rosa Rubio-Salvador, Vicente Escudero-Vilaplana, José Antonio Marcos Rodríguez, Irene Mangues-Bafalluy, Beatriz Bernárdez, Roberto Collado-Borrell

Int J Environ Res Public Health· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis